Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 4Unknown 3Terminated 3Recruiting 3Completed 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3CNS 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × brigatinib × Clear all
NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 17 charts
Thoracic

Lung Neoplasms

NCT02706626 2023-01-26

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Criterium, Inc.

Phase 2 Terminated
32 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04634110 2022-10-24

Brigatinib Before Brain Irradiation Trial (B3i Trial)

University of Colorado, Denver

Phase 2 Terminated
1 enrolled 6 charts
CNSThoracic

Brain Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡